Orchard Therapeutics Statistics

Total Valuation

Market Cap	n/a
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	+20.66%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	15.26
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.12, with a Debt / Equity ratio of 0.60.

Current Ratio	3.12
Quick Ratio	2.88
Debt / Equity	0.60
Debt / EBITDA	n/a
Debt / FCF	-0.51
Interest Coverage	-26.87

Financial Efficiency

Return on equity (ROE) is -71.50% and return on invested capital (ROIC) is -41.10%.

Return on Equity (ROE)	-71.50%
Return on Assets (ROA)	-29.23%
Return on Invested Capital (ROIC)	-41.10%
Return on Capital Employed (ROCE)	-66.72%
Revenue Per Employee	$131,560
Profits Per Employee	-$439,283
Employee Count	166
Asset Turnover	0.10
Inventory Turnover	17.73

Taxes

Income Tax	-140,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +165.50% in the last 52 weeks. The beta is 0.55, so ORTX's price volatility has been lower than the market average.

Beta (5Y)	0.55
52-Week Price Change	+165.50%
50-Day Moving Average	16.33
200-Day Moving Average	9.46
Relative Strength Index (RSI)	85.36
Average Volume (20 Days)	128,841

Short Selling Information

Short Interest	27,197
Short Previous Month	41,001
Short % of Shares Out	0.15%
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ORTX had revenue of $21.84 million and -$72.92 million in losses. Loss per share was -$4.24.

Revenue	21.84M
Gross Profit	-57.68M
Operating Income	-102.01M
Pretax Income	-73.06M
Net Income	-72.92M
EBITDA	-99.34M
EBIT	-102.01M
Loss Per Share	-$4.24

Full Income Statement

Balance Sheet

The company has $125.41 million in cash and $47.82 million in debt, giving a net cash position of $77.59 million.

Cash & Cash Equivalents	125.41M
Total Debt	47.82M
Net Cash	77.59M
Net Cash Per Share	n/a
Equity (Book Value)	80.26M
Book Value Per Share	3.53
Working Capital	104.55M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$93.32 million and capital expenditures -$1.09 million, giving a free cash flow of -$94.41 million.

Operating Cash Flow	-93.32M
Capital Expenditures	-1.09M
Free Cash Flow	-94.41M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	-264.11%
Operating Margin	-467.12%
Pretax Margin	-334.54%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

ORTX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-34.70%
Shareholder Yield	-34.70%
Earnings Yield	n/a
FCF Yield	n/a

Analyst Forecast

The average price target for ORTX is $21.67, which is 29.76% higher than the current price. The consensus rating is "Buy".

Price Target	$21.67
Price Target Difference	29.76%
Analyst Consensus	Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	31.76%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ORTX has an Altman Z-Score of -7.2 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.2
Piotroski F-Score	3